| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 1232 | 2021 |
| Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ... The Lancet Oncology 20 (8), 1124-1135, 2019 | 519 | 2019 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246-3256, 2022 | 492 | 2022 |
| Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR … G Gebhart, LE Lamberts, Z Wimana, C Garcia, P Emonts, L Ameye, ... Annals of oncology 27 (4), 619-624, 2016 | 381 | 2016 |
| Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis Y Bareche, D Venet, M Ignatiadis, P Aftimos, M Piccart, F Rothe, ... Annals of oncology 29 (4), 895-902, 2018 | 373 | 2018 |
| Delivering precision oncology to patients with cancer J Mateo, L Steuten, P Aftimos, F André, M Davies, E Garralda, J Geissler, ... Nature medicine 28 (4), 658-665, 2022 | 288 | 2022 |
| Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors J Lewin, JC Soria, A Stathis, JP Delord, S Peters, A Awada, PG Aftimos, ... Journal of Clinical Oncology 36 (30), 3007-3014, 2018 | 273 | 2018 |
| Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer A Bardia, SM Tolaney, K Punie, D Loirat, M Oliveira, K Kalinsky, A Zelnak, ... Annals of Oncology 32 (9), 1148-1156, 2021 | 255 | 2021 |
| HER2-low breast cancer: molecular characteristics and prognosis E Agostinetto, M Rediti, D Fimereli, V Debien, M Piccart, P Aftimos, ... Cancers 13 (11), 2824, 2021 | 186 | 2021 |
| Effect of the COVID-19 pandemic on cancer treatment and research KS Saini, B de Las Heras, J de Castro, R Venkitaraman, M Poelman, ... The Lancet. Haematology 7 (6), e432, 2020 | 156 | 2020 |
| Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative P Aftimos, M Oliveira, A Irrthum, D Fumagalli, C Sotiriou, EN Gal-Yam, ... Cancer Discovery 11 (11), 2796-2811, 2021 | 142 | 2021 |
| LBA15 Primary outcome of the phase III SYD985. 002/TULIP trial comparing [vic-] trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2 … CS Manich, J O'Shaughnessy, PG Aftimos, E Van Den Tweel, ... Annals of oncology 32, S1288, 2021 | 133 | 2021 |
| The AURORA initiative for metastatic breast cancer D Zardavas, M Maetens, A Irrthum, T Goulioti, K Engelen, D Fumagalli, ... British journal of cancer 111 (10), 1881-1887, 2014 | 104 | 2014 |
| Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer MA Locatelli, P Aftimos, EC Dees, PM LoRusso, MD Pegram, A Awada, ... Oncotarget 8 (2), 2320, 2016 | 95 | 2016 |
| Antibody-drug conjugates in breast cancer: a comprehensive review N Pondé, P Aftimos, M Piccart Current treatment options in oncology 20, 1-22, 2019 | 90 | 2019 |
| Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors MD Hellmann, N Bivi, B Calderon, T Shimizu, B Delafontaine, ZT Liu, ... Clinical Cancer Research 27 (10), 2773-2781, 2021 | 88 | 2021 |
| A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. C Saura, F Thistlethwaite, U Banerji, S Lord, V Moreno, I MacPherson, ... Journal of Clinical Oncology 36 (15_suppl), 1014-1014, 2018 | 75 | 2018 |
| Cardiotoxicity of systemic agents used in breast cancer F Ades, D Zardavas, AC Pinto, C Criscitiello, P Aftimos, E de Azambuja The Breast 23 (4), 317-328, 2014 | 73 | 2014 |
| EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer A Bardia, P Aftimos, T Bihani, AT Anderson-Villaluz, JA Jung, MG Conlan, ... Future oncology 15 (28), 3209-3218, 2019 | 67 | 2019 |
| Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies P Aftimos, C Rolfo, S Rottey, F Offner, D Bron, M Maerevoet, JC Soria, ... Clinical cancer research 23 (21), 6411-6420, 2017 | 64 | 2017 |
Christos SotiriouUniversité Libre de BruxellesVerifisert e-postadresse på bordet.be
